Skip to Content

Folotyn (pralatrexate) Disease Interactions

There are 2 disease interactions with Folotyn (pralatrexate):


Pralatrexate (Includes Folotyn) ↔ liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The safety, efficacy and pharmacokinetics of pralatrexate have not been evaluated in patients with hepatic impairment. Additionally, this drug can cause hepatotoxicity and liver function test abnormalities, which might require dose modification or discontinuation. Caution and monitoring is advised.


Pralatrexate (Includes Folotyn) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Patients with moderate to severe renal function impairment may be at greater risk of toxicity due to increased exposure. Patients should be monitored for renal function and toxicity and dosage should be adjusted accordingly. For patients with severe renal impairment (GFR 15 to <30), the recommended dose of pralatrexate is 15 mg/m2. Avoid the use of pralatrexate in patients with ESRD undergoing dialysis, unless the potential effect justifies the potential risk.

Folotyn (pralatrexate) drug interactions

There are 240 drug interactions with Folotyn (pralatrexate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.